I-Mab (IMAB) Competitors

I-Mab (NASDAQ:IMAB) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.

Is IMAB or CRVS more profitable?

I-Mab's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Corvus Pharmaceuticals	N/A	-70.71%	-45.90%

Which has preferable earnings & valuation, IMAB or CRVS?

Corvus Pharmaceuticals has lower revenue, but higher earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	20.47	-$206.44M	N/A	N/A
Corvus Pharmaceuticals	N/A	N/A	-$27.03M	-$0.93	-4.51

Which has more volatility & risk, IMAB or CRVS?

I-Mab has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

Does the MarketBeat Community favor IMAB or CRVS?

Corvus Pharmaceuticals received 232 more outperform votes than I-Mab when rated by MarketBeat users. However, 64.13% of users gave I-Mab an outperform vote while only 61.91% of users gave Corvus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
I-Mab	Outperform Votes 59 64.13%	Underperform Votes 33 35.87%
Corvus Pharmaceuticals	Outperform Votes 291 61.91%	Underperform Votes 179 38.09%

Do analysts prefer IMAB or CRVS?

I-Mab presently has a consensus target price of $8.00, indicating a potential upside of 718.83%. Corvus Pharmaceuticals has a consensus target price of $12.38, indicating a potential upside of 195.35%. Given I-Mab's higher possible upside, equities research analysts plainly believe I-Mab is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Corvus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Does the media prefer IMAB or CRVS?

In the previous week, I-Mab had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for I-Mab and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat I-Mab's score of 0.22 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do insiders & institutionals believe in IMAB or CRVS?

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Corvus Pharmaceuticals beats I-Mab on 8 of the 14 factors compared between the two stocks.